^
    3d
    Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2028 | Initiation date: Jan 2026 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Chr del(17p)
    |
    clonoSEQ
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • dexamethasone injection
    10d
    LINKER-SMM2: A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) (clinicaltrials.gov)
    P3, N=270, Not yet recruiting, Regeneron Pharmaceuticals
    New P3 trial
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    13d
    Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=75 --> 17
    Enrollment closed • Enrollment change
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    lenalidomide • carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection
    27d
    LINKER-MM5: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=915, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    bortezomib • carfilzomib • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    1m
    MAGNETISMM-5: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (clinicaltrials.gov)
    P3, N=944, Recruiting, Pfizer | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial primary completion date
    |
    lenalidomide • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) (clinicaltrials.gov)
    P2, N=40, Recruiting, University of Alabama at Birmingham | N=20 --> 40 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment change • Trial primary completion date • Minimal residual disease
    |
    lenalidomide • bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    FIL_DALYA: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (clinicaltrials.gov)
    P2, N=28, Recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Jan 2026 --> Jun 2027
    Trial completion date • IO biomarker
    |
    bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (clinicaltrials.gov)
    P2, N=160, Recruiting, University of Heidelberg Medical Center | Trial completion date: Aug 2028 --> Sep 2029 | Trial primary completion date: Feb 2027 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • JNJ-5322 • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • Xpovio (selinexor) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets)
    2ms
    CARTITUDE-2: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2028 --> Sep 2029
    Trial completion date
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel) • dexamethasone injection
    2ms
    The APOLLO Study: Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex (clinicaltrials.gov)
    P3, N=304, Completed, Stichting European Myeloma Network | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    PrE1005: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, PrECOG, LLC.
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Blenrep (belantamab mafodotin-blmf)